Emulate Secures $28.75M in Series B Funding to Expand Its Organ-Chip-Based Human Emulation System

Recently, Emulate, a company headquartered in Cambridge, UK, raised $28.75 million in its Series B financing round. The company’s product is a human body simulation system based on R&D chip circuits.



AA-battery-sized chip can predict human drug responses

Emulate’s organ-on-a-chip technology mimics the specialized functions of human organs, incorporating thousands of microfluidic channels that replicate the intricate networks found among human cells and tissues. Each chip is no larger than a single AA battery. “This microenvironment simulates the body’s internal conditions, and by applying external forces to introduce cells into the system, we enable them to behave as they would within the human body,” said James Coon, CEO of Emulate.

This organ-on-a-chip technology aims to enhance the efficiency of in vitro testing experiments on animals or humans. Emulate leverages algorithms and microfluidic chip technology to more accurately predict human responses to common drugs, chemicals, and pathogens.



The funds raised will be used to expand the design portfolio of chip products.

The company stated that it would use the funds to expand its portfolio of chip-based product designs. Currently, Emulate already possesses organ-on-a-chip technologies simulating human lungs, liver, intestines, and skin, with plans to extend these capabilities to the kidneys, heart, and brain. In addition, the company will develop chips capable of precise diagnosis for major diseases, including cancer, intestinal and microbial tissue lesions, and influenza viruses.

James Coon, CEO of Emulate, stated that the company aims to integrate its products across the pharmaceutical, chemical, and food sectors, while also developing direct-to-consumer offerings. Reportedly, the company completed a $12 million Series A financing round in 2014.